Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04651777 | Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma | PHASE3 | ACTIVE NOT_RECRUITING | 31 | — | — | Aug 8, 2022 | Dec 1, 2025 | Aug 29, 2025 | 1 | Canada |
Change in VDP
| Arm | Type | Description |
|---|---|---|
| Participants with poorly controlled moderate to severe asthma | EXPERIMENTAL | Participants with poorly controlled moderate to severe asthma will be evaluated during and after a six week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements. |
| Name | Type | Description |
|---|---|---|
| FF/UMEC/VI | DRUG | The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily. |
Inclusion Criteria: * Participant understands study procedures and is willing to participate in the study as indicated by the participant's signature * Provision of written, informed consent prior to any study specific procedures * Males and females with a clinical diagnosis of eosinophilic asthma ...